ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression.

@article{Abbeele2012ACRIN60,
  title={ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression.},
  author={Annick D. Van den Abbeele and Constantine G Gatsonis and Daniel J de Vries and Yulia Melenevsky and Agnieszka Szot-Barnes and Jeffrey T. Yap and Andrew K. Godwin and Lori Rink and Min Huang and Meridith Blevins and Jorean D Sicks and Burton Eisenberg and Barry A. Siegel},
  journal={Journal of nuclear medicine : official publication, Society of Nuclear Medicine},
  year={2012},
  volume={53 4},
  pages={567-74}
}
UNLABELLED We investigated the correlation between metabolic response by (18)F-FDG PET and objective response, glucose transporter type 4 (GLUT4) expression, and KIT/PDGFRA mutation status in patients with gastrointestinal stromal tumor undergoing neoadjuvant imatinib mesylate therapy. METHODS (18)F-FDG PET was performed at baseline, 1-7 d, and 4 or 8 wk after imatinib mesylate initiation. Best objective response was defined by version 1.0 of the Response Evaluation Criteria in Solid Tumors… CONTINUE READING
14 Extracted Citations
37 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 14 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 37 references

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

  • GD Demetri, vonMehrenM, CD Blanke
  • N Engl J Med
  • 2002
Highly Influential
4 Excerpts

Similar Papers

Loading similar papers…